First-in-Human

SAN DIEGO and SUZHOU, China — September 22, 2026 Adagene announced that China’s National Medical Products Administration (NMPA) has...

ALAMEDA, Calif. — September 14, 2026 Santa Ana Bio announced that the first cohort has been dosed in the...

MARLBOROUGH, Mass., August 12, 2026 Sumitomo Pharma America, Inc. announced that the first patient has received treatment with DSP-3077...

BURLINGTON, Mass., August 12, 2026 Bone Biologics Corporation announced that its rhNELL-1 protein has achieved a validated shelf life...

SAN DIEGO, July 15, 2026 Sinopia Biosciences announced the publication of preclinical research in Science Translational Medicine supporting SB-0110,...

BOSTON, July 14, 2026 Atea Pharmaceuticals announced the initiation of a first-in-human Phase 1 clinical trial evaluating AT-587, an...

OSLO, Norway, July 13, 2026 Zelluna announced that the first patient has been dosed in the ZIMA-101 Phase 1...

SEATTLE, July 1, 2026 Sana Biotechnology, Inc. announced that new clinical data from a first-in-human investigator-sponsored study evaluating UP421,...

BALTIMORE, June 29, 2026 CraniUS Therapeutics has received an initial $1.1 million award through the National Institutes of Health...

SHANGHAI, April 10, 2026 Shanghai Ark Biopharmaceutical Co., Ltd. has announced a key clinical milestone with the successful dosing...